Melanoma/Skin Cancer – Expert Insights from Rodabe N. Amaria

Expert Interview

Dr Amaria discusses her ASCO21 highlights for melanoma, including results from the neoadjuvant and adjuvant nivolumab data with anti-LAG3 antibody relatlimab for patients with with clinical stage III or oligometastatic stage IV melanoma (abstract 9502), results from the RELATIVITY-047 study –the first randomized phase III trial to evaluate the IO agents anti–PD-1 therapy nivolumab plus relatlimab – a LAG-3-blocking antibody-in patients with untreated, unresectable or metastatic melanoma (abstract 9503). She also provides her clinical insights about the updated findings from the LEAP-004 phase II study evaluating lenvatinib plus pembrolizumab in advanced melanoma following prior PD-(L)1 therapy (abstract 9504) and the phase II efficacy and safety study of lifileucel adoptive T-cell therapy in patients with advanced melanoma (abstract 9505).
Interviewee: Rodabe N. Amaria, MD
Affiliation(s): Department of Melanoma - Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
Disclosures: Consulting or Advisory Role: Iovance Biotherapeutics, Nektar, Novartis; Research Funding: Array BioPharma (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), iovance Biotherapeutics (Inst), Merck (Inst), Novartis (Inst)
Interview Date: June 14, 2021
Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Read full disclaimer here.
Share:
Share on facebook
Share on twitter
Share on linkedin

Abstracts Referenced In This Expert Interview

Oral Abstract Session

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)

Presenter: Evan J. Lipson
Presentation Date: June 6, 2021
Abstract Number: 9503
Oral Abstract Session

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy

Presenter: James Larkin
Presentation Date: June 6, 2021
Abstract Number: 9505
Oral Abstract Session

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004

Presenter: Ana Maria Arance
Presentation Date: June 6, 2021
Abstract Number: 9504
Oral Abstract Session

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma

Presenter: Rodabe Navroze Amaria, MD
Presentation Date: June 6, 2021
Abstract Number: 9502

Other Melanoma/Skin Cancer Content

Oral Abstract Session

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)

Presenter: Evan J. Lipson
Presentation Date: June 6, 2021
Abstract Number: 9503
Oral Abstract Session

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy

Presenter: James Larkin
Presentation Date: June 6, 2021
Abstract Number: 9505
Oral Abstract Session

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004

Presenter: Ana Maria Arance
Presentation Date: June 6, 2021
Abstract Number: 9504
Oral Abstract Session

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma

Presenter: Rodabe Navroze Amaria, MD
Presentation Date: June 6, 2021
Abstract Number: 9502
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare